Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Sell
45
IDYA Quote, Financials, Valuation and Earnings
Last price:
$35.86
Seasonality move
:
-23.57%
Day range:
$35.58 - $36.88
52-week range:
$13.45 - $39.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.76x
P/B ratio:
2.88x
Volume:
820.6K
Avg. volume:
969.7K
1-year change:
57.75%
Market cap:
$3.1B
Revenue:
$7M
EPS (TTM):
-$1.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$5.1M | -$0.94 | -15.05% | -14.89% | $49.71 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.63 | -- | -60.91% | $185.29 |
|
KMTS
Kestra Medical Technologies Ltd.
|
$22.9M | -$0.60 | 51.57% | -24.07% | $29.00 |
|
PFE
Pfizer Inc.
|
$14B | $0.74 | 2.05% | 43.22% | $28.66 |
|
RZLT
Rezolute, Inc.
|
-- | -$0.16 | -- | -40.23% | $4.25 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$375.7M | $0.67 | -49.56% | -91.57% | $20.74 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$35.84 | $49.71 | $3.1B | -- | $0.00 | 0% | 14.76x |
|
BLTE
Belite Bio, Inc.
|
$155.11 | $185.29 | $5.8B | -- | $0.00 | 0% | -- |
|
KMTS
Kestra Medical Technologies Ltd.
|
$22.85 | $29.00 | $1.1B | -- | $0.00 | 0% | 15.80x |
|
PFE
Pfizer Inc.
|
$25.65 | $28.66 | $145.8B | 14.95x | $0.43 | 6.71% | 2.33x |
|
RZLT
Rezolute, Inc.
|
$2.73 | $4.25 | $253.1M | -- | $0.00 | 0% | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
$21.13 | $20.74 | $2.2B | 20.50x | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.708 | 1.14% | 12.20x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.792 | 0.02% | 34.17x |
|
KMTS
Kestra Medical Technologies Ltd.
|
21.45% | 0.000 | 3.43% | 5.32x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
|
RZLT
Rezolute, Inc.
|
0.98% | 4.682 | 0.17% | 14.91x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.411 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
KMTS
Kestra Medical Technologies Ltd.
|
$11.4M | -$31.8M | -77.65% | -105.99% | -140.73% | -$25.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
RZLT
Rezolute, Inc.
|
-$8K | -$19.8M | -62.88% | -63.8% | -- | -$17.4M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
IDEAYA Biosciences, Inc. vs. Competitors
-
Which has Higher Returns IDYA or BLTE?
Belite Bio, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About IDYA or BLTE?
IDEAYA Biosciences, Inc. has a consensus price target of $49.71, signalling upside risk potential of 38.69%. On the other hand Belite Bio, Inc. has an analysts' consensus of $185.29 which suggests that it could grow by 19.45%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Belite Bio, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.14 2 0 BLTEBelite Bio, Inc.5 0 0 -
Is IDYA or BLTE More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.052, which suggesting that the stock is 94.83% less volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IDYA or BLTE?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or BLTE?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Belite Bio, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Belite Bio, Inc.'s net income of -$21.7M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.76x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.76x -- $207.8M $119.2M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns IDYA or KMTS?
Kestra Medical Technologies Ltd. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -145.29%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B KMTSKestra Medical Technologies Ltd.50.63% -$0.64 $208.9M -
What do Analysts Say About IDYA or KMTS?
IDEAYA Biosciences, Inc. has a consensus price target of $49.71, signalling upside risk potential of 38.69%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.00 which suggests that it could grow by 26.92%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe IDEAYA Biosciences, Inc. is more attractive than Kestra Medical Technologies Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.14 2 0 KMTSKestra Medical Technologies Ltd.5 1 0 -
Is IDYA or KMTS More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.052, which suggesting that the stock is 94.83% less volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IDYA or KMTS?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDYA or KMTS?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.76x versus 15.80x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.76x -- $207.8M $119.2M KMTSKestra Medical Technologies Ltd.15.80x -- $22.6M -$32.8M
-
Which has Higher Returns IDYA or PFE?
Pfizer Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of 21.32%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About IDYA or PFE?
IDEAYA Biosciences, Inc. has a consensus price target of $49.71, signalling upside risk potential of 38.69%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.14 2 0 PFEPfizer Inc.7 15 1 -
Is IDYA or PFE More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.052, which suggesting that the stock is 94.83% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock IDYA or PFE?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or PFE?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. IDEAYA Biosciences, Inc.'s net income of $119.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.76x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.76x -- $207.8M $119.2M PFEPfizer Inc.2.33x 14.95x $16.7B $3.6B
-
Which has Higher Returns IDYA or RZLT?
Rezolute, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Rezolute, Inc.'s return on equity of -63.8%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B RZLTRezolute, Inc.-- -$0.18 $148.6M -
What do Analysts Say About IDYA or RZLT?
IDEAYA Biosciences, Inc. has a consensus price target of $49.71, signalling upside risk potential of 38.69%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 55.68%. Given that Rezolute, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe Rezolute, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.14 2 0 RZLTRezolute, Inc.5 4 0 -
Is IDYA or RZLT More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.052, which suggesting that the stock is 94.83% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 61.035%.
-
Which is a Better Dividend Stock IDYA or RZLT?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or RZLT?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Rezolute, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Rezolute, Inc.'s net income of -$18.2M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.76x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.76x -- $207.8M $119.2M RZLTRezolute, Inc.-- -- -- -$18.2M
-
Which has Higher Returns IDYA or SRPT?
Sarepta Therapeutics, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -45.06%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About IDYA or SRPT?
IDEAYA Biosciences, Inc. has a consensus price target of $49.71, signalling upside risk potential of 38.69%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.74 which suggests that it could fall by -1.85%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.14 2 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is IDYA or SRPT More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.052, which suggesting that the stock is 94.83% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.
-
Which is a Better Dividend Stock IDYA or SRPT?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or SRPT?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.76x versus 0.90x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.76x -- $207.8M $119.2M SRPTSarepta Therapeutics, Inc.0.90x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
